Expert Rev Cardiovasc Ther. 2026 Apr 29. doi: 10.1080/14779072.2026.2665194. Online ahead of print.
ABSTRACT
BACKGROUND: Despite statin therapy, cardiovascular disease remains a leading cause of mortality. CSL112 enhances HDL function and reverse cholesterol transport, offering a novel strategy for atherosclerotic cardiovascular disease (CVD).
METHODS: Following PRISMA guidelines, databases including PubMed, the Cochrane Library, Scopus, Google Scholar and EMBASE were searched from inception to May 2025 for studies evaluating efficacy and safety of CSL112 in adults at risk of Atherosclerotic CVD. Data were analyzed using RevMan version 5.4 with a random-effects model.
RESULTS: Six trials (n = 1,824) showed that CSL112 significantly increased total cholesterol efflux capacity (CEC), most notably with the 6 g dose (MD 11.90; p < 0.00001), including ABCA1-dependent (MD 5.88; p < 0.00001) and ABCA1-independent CEC (MD 4.68; p < 0.0001) at 2 hours. HDL-C levels increased significantly (MD 6.89; p < 0.00001) without meaningful change in apolipoprotein A-I. Safety analyses showed no increased risk of serious adverse events (RR 1.05) or treatment-emergent adverse events (RR 0.88) versus placebo.
CONCLUSION: CSL112 significantly enhances CEC and HDL-C levels with favorable safety profile with the 6 g dose at 2 hours, supporting its use as adjunctive therapy for immediate cardiovascular protection. Large outcome-driven trials are warranted to define long-term clinical benefits.
PMID:42056068 | DOI:10.1080/14779072.2026.2665194